The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas

Our group previously demonstrated that sarcoma cell lines were insensitive to epidermal growth factor receptor (EGFR) inhibitor gefitinib monotherapy. PENAO, an anti-tumour metabolic compound created in our laboratory, is currently in clinical trials. Considering the positive regulation of tumour en...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Wang, Xiaochun, Yeo, Reichelle X., Hogg, Philip J., Goldstein, David, Crowe, Philip, Dilda, Pierre J., Yang, Jia-Lin
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2020
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6967775/
https://ncbi.nlm.nih.gov/pubmed/32002123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27416
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items